Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 111

1.

The association of atrophy in baseline prostate biopsy and lower prostate cancer grade in radical prostatectomy specimens.

Freitas DMO, Andriole GL, Castro-Santamaria R, Freedland SJ, Moreira DM.

Scand J Urol. 2019 Feb 14:1-5. doi: 10.1080/21681805.2018.1551244. [Epub ahead of print]

PMID:
30762450
2.

Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database.

Aminsharifi A, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Polascik TJ, Freedland SJ.

Clin Genitourin Cancer. 2019 Feb;17(1):e140-e149. doi: 10.1016/j.clgc.2018.09.020. Epub 2018 Oct 4.

PMID:
30366879
3.

Obesity, risk of biochemical recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database.

Freedland SJ, Branche BL, Howard LE, Hamilton RJ, Aronson WJ, Terris MK, Cooperberg MR, Amling CL, Kane CJ; SEARCH Database Study Group.

BJU Int. 2018 Oct 22. doi: 10.1111/bju.14594. [Epub ahead of print]

PMID:
30347135
4.

Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the Prostate Specific Antigen is in the Diagnostic Gray Zone: Defining the Optimum Cutoff Point Stratified by Race and Body Mass Index.

Aminsharifi A, Howard L, Wu Y, De Hoedt A, Bailey C, Freedland SJ, Polascik TJ.

J Urol. 2018 Oct;200(4):758-766. doi: 10.1016/j.juro.2018.05.016. Epub 2018 Jul 6.

PMID:
29758219
5.

Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

Vidal AC, Howard LE, de Hoedt A, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Freedland SJ.

BJU Int. 2018 Jul;122(1):76-82. doi: 10.1111/bju.14193. Epub 2018 Apr 10.

PMID:
29521009
6.

Predictors of operative time during radical retropubic prostatectomy and robot-assisted laparoscopic prostatectomy.

Simon RM, Howard LE, Moreira DM, Terris MK, Kane CJ, Aronson WJ, Amling CL, Cooperberg MR, Freedland SJ.

Int J Urol. 2017 Aug;24(8):618-623. doi: 10.1111/iju.13393. Epub 2017 Jul 11.

7.

Among Active Surveillance Candidates does Obesity Influence Tumor Aggressiveness and/or Location?

Freedland AR, Freedland SJ.

J Urol. 2017 Jul;198(1):4-5. doi: 10.1016/j.juro.2017.04.074. Epub 2017 Apr 22. No abstract available.

PMID:
28441515
8.

Is Body Mass Index the Best Adiposity Measure for Prostate Cancer Risk? Results From a Veterans Affairs Biopsy Cohort.

Guerrios-Rivera L, Howard L, Frank J, De Hoedt A, Beverly D, Grant DJ, Hoyo C, Freedland SJ.

Urology. 2017 Jul;105:129-135. doi: 10.1016/j.urology.2017.03.042. Epub 2017 Apr 10.

9.

Waist-hip Ratio (WHR), a Better Predictor for Prostate Cancer than Body Mass Index (BMI): Results from a Chinese Hospital-based Biopsy Cohort.

Tang B, Han CT, Zhang GM, Zhang CZ, Yang WY, Shen Y, Vidal AC, Freedland SJ, Zhu Y, Ye DW.

Sci Rep. 2017 Mar 8;7:43551. doi: 10.1038/srep43551.

10.

Impact of carbohydrate restriction in the context of obesity on prostate tumor growth in the Hi-Myc transgenic mouse model.

Allott EH, Macias E, Sanders S, Knudsen BS, Thomas GV, Hursting SD, Freedland SJ.

Prostate Cancer Prostatic Dis. 2017 Jun;20(2):165-171. doi: 10.1038/pcan.2016.73. Epub 2017 Feb 28.

11.

Association of Obesity-Related Hemodilution of Prostate-Specific Antigen, Dihydrotestosterone, and Testosterone.

Klaassen Z, Howard LE, Moreira DM, Andriole GL Jr, Terris MK, Freedland SJ.

Prostate. 2017 Apr;77(5):466-470. doi: 10.1002/pros.23285. Epub 2016 Dec 19.

PMID:
27990661
12.

Obesity and Prostate Cancer: A Focused Update on Active Surveillance, Race, and Molecular Subtyping.

Vidal AC, Freedland SJ.

Eur Urol. 2017 Jul;72(1):78-83. doi: 10.1016/j.eururo.2016.10.011. Epub 2016 Oct 19. Review.

13.

Obesity and prostate cancer-specific mortality after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

Vidal AC, Howard LE, Sun SX, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Freedland SJ.

Prostate Cancer Prostatic Dis. 2017 Mar;20(1):72-78. doi: 10.1038/pcan.2016.47. Epub 2016 Oct 4.

14.

The association between sexual function and prostate cancer risk in US veterans.

Zapata DF, Howard LE, Frank J, Simon RM, Hoyo C, Grant DJ, Freedland SJ, Vidal AC.

Asian J Androl. 2017 Mar-Apr;19(2):191-195. doi: 10.4103/1008-682X.184869.

15.

Effect of body mass index on the performance characteristics of PSA-related markers to detect prostate cancer.

Zhu Y, Han CT, Zhang GM, Liu F, Ding Q, Xu JF, Vidal AC, Freedland SJ, Ng CF, Ye DW.

Sci Rep. 2016 Jan 12;6:19034. doi: 10.1038/srep19034.

16.

Utilization and impact of surgical technique on the performance of pelvic lymph node dissection at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database.

McGinley KF, Sun X, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ.

Int J Urol. 2016 Mar;23(3):241-6. doi: 10.1111/iju.13027. Epub 2015 Dec 14.

17.

Metformin use and risk of prostate cancer: results from the REDUCE study.

Feng T, Sun X, Howard LE, Vidal AC, Gaines AR, Moreira DM, Castro-Santamaria R, Andriole GL, Freedland SJ.

Cancer Prev Res (Phila). 2015 Nov;8(11):1055-60. doi: 10.1158/1940-6207.CAPR-15-0141. Epub 2015 Sep 9.

18.

Agent Orange and long-term outcomes after radical prostatectomy.

Ovadia AE, Terris MK, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ, Abern MR.

Urol Oncol. 2015 Jul;33(7):329.e1-6. doi: 10.1016/j.urolonc.2015.04.012. Epub 2015 May 18.

19.

Smoking is a predictor of adverse pathological features at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database.

Zapata DF, Howard LE, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Freedland SJ.

Int J Urol. 2015 Jul;22(7):658-62. doi: 10.1111/iju.12773. Epub 2015 Apr 14.

20.

Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death.

Gerdtsson A, Poon JB, Thorek DL, Mucci LA, Evans MJ, Scardino P, Abrahamsson PA, Nilsson P, Manjer J, Bjartell A, Malm J, Vickers A, Freedland SJ, Lilja H, Ulmert D.

Eur Urol. 2015 Dec;68(6):1076-82. doi: 10.1016/j.eururo.2015.03.017. Epub 2015 Mar 18.

Supplemental Content

Loading ...
Support Center